Summit Trail Advisors LLC Has $796,000 Stake in CME Group Inc. (NASDAQ:CME)

Summit Trail Advisors LLC grew its position in CME Group Inc. (NASDAQ:CME) by 9.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,608 shares of the financial services provider’s stock after purchasing an additional 319 shares during the period. Summit Trail Advisors LLC’s holdings in CME Group were worth $796,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of CME. Y.D. More Investments Ltd acquired a new position in CME Group during the 2nd quarter worth approximately $36,000. McClarren Financial Advisors Inc. grew its position in CME Group by 66.1% in the second quarter. McClarren Financial Advisors Inc. now owns 196 shares of the financial services provider’s stock valued at $39,000 after purchasing an additional 78 shares in the last quarter. Asset Dedication LLC increased its stake in CME Group by 515.2% in the 2nd quarter. Asset Dedication LLC now owns 203 shares of the financial services provider’s stock valued at $40,000 after buying an additional 170 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its position in CME Group by 62.2% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 193 shares of the financial services provider’s stock worth $43,000 after buying an additional 74 shares in the last quarter. Finally, Bank & Trust Co acquired a new position in shares of CME Group during the 2nd quarter worth about $76,000. 87.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Timothy S. Bitsberger sold 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $226.96, for a total transaction of $226,960.00. Following the completion of the sale, the director now owns 10,589 shares of the company’s stock, valued at $2,403,279.44. This represents a 8.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Bryan T. Durkin sold 7,593 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the completion of the transaction, the director now owns 55,607 shares of the company’s stock, valued at $11,932,706.13. The trade was a 12.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,621 shares of company stock worth $3,441,063 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

CME has been the topic of several analyst reports. Bank of America upped their target price on CME Group from $177.00 to $180.00 and gave the stock an “underperform” rating in a report on Thursday, October 3rd. Barclays upped their price objective on CME Group from $219.00 to $231.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 24th. Morgan Stanley raised their target price on shares of CME Group from $210.00 to $233.00 and gave the company an “equal weight” rating in a research note on Thursday, October 17th. Redburn Atlantic lowered shares of CME Group from a “buy” rating to a “neutral” rating and set a $244.00 price target on the stock. in a research report on Tuesday, October 8th. Finally, Citigroup lifted their price objective on shares of CME Group from $250.00 to $255.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, CME Group currently has an average rating of “Hold” and a consensus target price of $224.47.

CME Group Price Performance

CME Group stock opened at $229.37 on Tuesday. The company has a market capitalization of $82.66 billion, a price-to-earnings ratio of 24.12, a PEG ratio of 5.28 and a beta of 0.55. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.09. CME Group Inc. has a 12 month low of $190.70 and a 12 month high of $230.74. The stock’s 50 day moving average is $223.86 and its 200-day moving average is $211.19.

CME Group (NASDAQ:CME) last issued its quarterly earnings data on Wednesday, October 23rd. The financial services provider reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.03. CME Group had a return on equity of 13.39% and a net margin of 57.34%. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same period in the prior year, the firm posted $2.25 EPS. The company’s revenue for the quarter was up 18.4% on a year-over-year basis. Equities research analysts expect that CME Group Inc. will post 10.22 EPS for the current year.

CME Group Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Shareholders of record on Monday, December 9th will be issued a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a yield of 2.01%. The ex-dividend date is Monday, December 9th. CME Group’s dividend payout ratio is currently 48.37%.

CME Group Company Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.